Dec 7 (Reuters) - CSL Ltd CSL.AX :
* SEQIRUS - IMMUNOGENICITY OF TWO DOSES OF H5N1 ELICITED STRONG IMMUNE RESPONSE IN PEDIATRIC GROUP (6 MONTHS TO 17 YEARS OLD)
* SEQIRUS - IMMUNOGENICITY OF TWO DOSES OF H5N1 ELICITED A STRONG IMMUNE RESPONSE IN ADULTS (≥ 18 YEARS TO 64 YEARS OLD)
* SEQIRUS - IMMUNOGENICITY OF TWO DOSES OF H5N1 ELICITED A STRONG IMMUNE RESPONSE IN OLDER ADULTS (≥ 65 YEARS OLD)
* SEQIRUS - SEPARATE SAFETY ANALYSIS OF H5N1 IN PEDIATRIC , ADULT AND OLDER ADULTS, DEMONSTRATED THAT VACCINE WAS WELL TOLERATED IN THESE AGE GROUPS